Tag: science

Washington, DC, Aug. 02, 2025 (GLOBE NEWSWIRE) --

Link to ThinkCareBelieve's Article:  https://thinkcarebelieve.blog/2025/08/02/week-28-americas-success-in-president-trumps-care/

Experts Reveal 2025 Dog Gut Health Findings, Ingredient Transparency Push, and the Rise of Targeted Canine Probiotics

Discover the official launch of Arialief in United States, UK, NZ, Canada and Australia, a new supplement developed to support those suffering from neuropathy and sciatic nerve discomfort. Learn how this science-backed formulation aims to provide natural relief and improve nerve health.

Matsato Kitchen Knife official launch of the Matsato Knife a high-performance culinary blade crafted for chefs and home cooks across Australia, the United States, Canada, and the UK. Engineered for razor-sharp precision, ergonomic comfort, and long-lasting durability. transform your cooking experience

IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States.

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

MERIDIAN, Idaho, Aug. 01, 2025 (GLOBE NEWSWIRE) -- PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today announced that it has repurchased 3,736,170 of its outstanding shares on the open market in the period from July 07, 2025, up to and including July 28, 2025.

Leveraging the feasibility results from the NRCan-funded project, the project team is now aiming to complete the front-end engineering design for three facilities to convert wood waste feedstock into renewable diesel fuel

En s’appuyant sur les résultats de faisabilité du projet financé par RNCan, l’équipe du projet vise désormais à achever la conception technique préliminaire de trois installations destinées à convertir les déchets de bois en carburant diesel renouvelable

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.